Common Contracts
10 similar Release Agreement contracts by Celladon Corp, HTG Molecular Diagnostics, Inc
Via Email Only (smcmeans@htgmolecular.com)Release Agreement • February 25th, 2015 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments
On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 12, 2012 (the “Prior Agreement”), as provided in Section 12 below.
Via Email Only (tjjohnson@htgmolecular.com)Release Agreement • February 25th, 2015 • HTG Molecular Diagnostics, Inc • Laboratory analytical instruments
On behalf of HTG Molecular Diagnostics, Inc. (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (this “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 7, 2008 (the “Prior Agreement”), as provided in Section 12 below.
August 31, 2013 Ryan K. TakeyaRelease Agreement • January 28th, 2014 • Celladon Corp • Biological products, (no disgnostic substances)
On behalf of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 30, 2012 (the “Prior Agreement”), as provided in Section 12 below.
August 31, 2013 Jeffrey J. RudyRelease Agreement • January 28th, 2014 • Celladon Corp • Biological products, (no disgnostic substances)
On behalf of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated May 3, 2006 (the “Prior Agreement”), as provided in Section 12 below.
August 30, 2013 Krisztina M. Zsebo, Ph.D.Release Agreement • January 28th, 2014 • Celladon Corp • Biological products, (no disgnostic substances) • California
On behalf of the Board of Directors (the “Board”) of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated July 2, 2012 (the “Prior Agreement”), as provided in Section 12 below.
August 31, 2013 Rebecque LabaRelease Agreement • January 28th, 2014 • Celladon Corp • Biological products, (no disgnostic substances)
On behalf of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated September 24, 2007, as amended in April 2012 (the “Prior Agreement”), as provided in Section 12 below.
August 31, 2013 Ryan K. TakeyaRelease Agreement • October 11th, 2013 • Celladon Corp • Biological products, (no disgnostic substances)
On behalf of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated January 30, 2012 (the “Prior Agreement”), as provided in Section 12 below.
August 30, 2013 Krisztina M. Zsebo, Ph.D.Release Agreement • September 6th, 2013 • Celladon Corp • Biological products, (no disgnostic substances) • California
On behalf of the Board of Directors (the “Board”) of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated July 2, 2012 (the “Prior Agreement”), as provided in Section 12 below.
August 31, 2013 Rebecque LabaRelease Agreement • September 6th, 2013 • Celladon Corp • Biological products, (no disgnostic substances)
On behalf of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated September 24, 2007, as amended in April 2012 (the “Prior Agreement”), as provided in Section 12 below.
August 31, 2013 Jeffrey J. RudyRelease Agreement • September 6th, 2013 • Celladon Corp • Biological products, (no disgnostic substances)
On behalf of Celladon Corporation (the “Company”), I am pleased to offer you continued employment at the Company on the terms set forth in this letter agreement (the “Agreement”). Subject to your acceptance by signing below, this Agreement will become effective upon the date of the underwriting agreement between the Company and the underwriter(s) managing the initial public offering of the Company’s common stock, pursuant to which such common stock is priced for the initial public offering (the “Effective Date”). As of the Effective Date, this Agreement replaces and supersedes in its entirety the letter agreement between you and the Company dated May 3, 2006 (the “Prior Agreement”), as provided in Section 12 below.
